Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2025-12-26 @ 3:11 AM
Study NCT ID:
NCT06817720
Status:
RECRUITING
Last Update Posted:
2025-10-15
First Post:
2025-02-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Sponsor:
M.D. Anderson Cancer Center
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2025-10-13
Start Date Type:
ACTUAL
Primary Completion Date:
2027-03-07
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-03-07
Completion Date Type:
ESTIMATED
First Submit Date:
2025-02-04
First Submit QC Date:
None
Study First Post Date:
2025-02-10
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-13
Last Update Post Date:
2025-10-15
Last Update Post Date Type:
ESTIMATED